Title : The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.

Pub. Date : 2013 Mar

PMID : 23018163






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In vitro assays have demonstrated PDE5-Is by regulating cyclic guanosine monophosphate (cGMP) degradation and enhancing the nitric oxide/cGMP signaling pathway to relax human smooth muscle strips from the prostate, bladder, and LUT arteries. Nitric Oxide phosphodiesterase 5A Homo sapiens